51 related articles for article (PubMed ID: 5481518)
1. Management of cirrhotic ascites.
Pedersen JS; Bendtsen F; Møller S
Ther Adv Chronic Dis; 2015 May; 6(3):124-37. PubMed ID: 25954497
[TBL] [Abstract][Full Text] [Related]
2. Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy.
Roscioni SS; de Zeeuw D; Bakker SJ; Lambers Heerspink HJ
Nat Rev Nephrol; 2012 Dec; 8(12):691-9. PubMed ID: 23070570
[TBL] [Abstract][Full Text] [Related]
3. Guidelines on the management of ascites in cirrhosis.
Moore KP; Aithal GP
Gut; 2006 Oct; 55 Suppl 6(Suppl 6):vi1-12. PubMed ID: 16966752
[No Abstract] [Full Text] [Related]
4. The kidney and liver diseases.
Wilkinson SP
J Clin Pathol; 1981 Nov; 34(11):1241-4. PubMed ID: 7320220
[No Abstract] [Full Text] [Related]
5. Renin-angiotensin-aldosterone system in cirrhosis.
Wilkinson SP; Williams R
Gut; 1980 Jun; 21(6):545-54. PubMed ID: 7000629
[TBL] [Abstract][Full Text] [Related]
6. The hepatorenal syndrome revisited.
Wilkinson SP
Intensive Care Med; 1987; 13(3):145-7. PubMed ID: 3584643
[No Abstract] [Full Text] [Related]
7. Clinical and hormonal conditions associated with sodium retention in cirrhotic patients with ascites. Evaluation by univariate and multivariate analyses.
Gentile S; Angelico M; Chiappini MG; Peruzzi G; Vulterini S
Dig Dis Sci; 1987 Jun; 32(6):569-76. PubMed ID: 3552505
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of ascites and hepatorenal syndrome.
Wilkinson SP; Moore KP; Arroyo V
Gut; 1991 Sep; Suppl(Suppl):S12-7. PubMed ID: 1833293
[No Abstract] [Full Text] [Related]
9. Pharmacotherapy of ascites associated with cirrhosis.
Ginès P; Arrovo V; Rodés J
Drugs; 1992 Mar; 43(3):316-32. PubMed ID: 1374317
[TBL] [Abstract][Full Text] [Related]
10. Renal retention of sodium in cirrhosis and fulminant hepatic failure.
Wilkinson SP; Moodie H; Alam A; Williams R
Postgrad Med J; 1975 Aug; 51(598):527-31. PubMed ID: 1234336
[TBL] [Abstract][Full Text] [Related]
11. Diuretics: mechanism of action and clinical application.
Davies DL; Wilson GM
Drugs; 1975; 9(3):178-226. PubMed ID: 1092541
[TBL] [Abstract][Full Text] [Related]
12. The urinary sodium: potassium ratio and response to diuretics in resistant oedema.
Alexander WD; Branch RA; Levine DF; Hartog M
Postgrad Med J; 1977 Mar; 53(617):117-21. PubMed ID: 323834
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of high-dose spironolactone therapy in patients with chronic liver disease and relatively refractory ascites.
Campra JL; Reynolds TB
Am J Dig Dis; 1978 Nov; 23(11):1025-30. PubMed ID: 31086
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone diuresis in patients with cirrhosis and ascites.
Eggert RC
Br Med J; 1970 Nov; 4(5732):401-3. PubMed ID: 5481518
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system.
Pérez-Ayuso RM; Arroyo V; Planas R; Gaya J; Bory F; Rimola A; Rivera F; Rodés J
Gastroenterology; 1983 May; 84(5 Pt 1):961-8. PubMed ID: 6339312
[TBL] [Abstract][Full Text] [Related]
16. Use of piretanide, a new loop diuretic, in cirrhosis with ascites: relationship between the diuretic response and the plasma aldosterone level.
Arroyo V; Bosch J; Casamitjana R; Cabrera J; Rivera F; Rodés J
Gut; 1980 Oct; 21(10):855-9. PubMed ID: 7439805
[TBL] [Abstract][Full Text] [Related]
17. A randomized comparison of metoclopramide and domperidone on plasma aldosterone concentration and on spironolactone-induced diuresis in ascitic cirrhotic patients.
D'Arienzo A; Ambrogio G; Di Siervi P; Perna E; Squame G; Mazzacca G
Hepatology; 1985; 5(5):854-7. PubMed ID: 4029895
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
